查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1935248

奈米医学市场按载体类型、应用、分销管道和地区划分

Nanopharmaceuticals Market, By Carrier Type, By Application, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3个工作天内

价格
简介目录

奈米医药市场预计在 2026 年达到 1,890 亿美元，预计到 2033 年将达到 7,620 亿美元，2026 年至 2033 年的年复合成长率（CAGR）为 22.1%。

报告范围 报告详情
基准年： 2025 2026年市场规模： 1890亿美元
历史数据时期： 2020-2024 预测期： 2026-2033
预测期（2026-2033 年）复合年增长率： 22.10% 2033 年的预测值： 7620亿美元

奈米药物是粒径小于1微米的新型药物，其作用机制基于奈米技术。奈米药物广泛应用于药物递送，既可作为治疗化合物的载体，也可本身作为治疗化合物。奈米药物的设计目标是针对特定的细胞、组织或器官。

市场动态

心血管疾病、癌症和感染疾病的日益普及是推动奈米药物市场成长的主要因素。根据世界卫生组织（世卫组织）2018年9月发布的情况说明书，2017年全球估计有1,000万例结核病病例和160万例死亡病例。此外，奈米药物相对于传统药物的优势预计也将推动市场成长。奈米药物可以穿过血脑障壁，到达大脑的远端区域。此外，透过提高化合物的低溶解度，可以进一步增强其性能。

本次调查的主要特点

  • 本报告对奈米医学市场进行了详细分析，并以 2017 年为基准年，给出了预测期（2018-2026 年）的市场规模和复合年增长率。
  • 它还重点介绍了各个细分市场的潜在商机，并解释了该市场具有吸引力的投资提案矩阵。
  • 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业的竞争策略的重要见解。
  • 该报告根据公司概况、财务表现、产品系列、市场占有率、分销策略、关键发展、策略和未来计划等参数，对全球奈米医学市场的主要参与者进行了分析。
  • 本报告的研究结果将使负责人和经营团队能够就未来的产品发布、技术升级、市场扩张和行销策略做出明智的决策。
  • 这份全球奈米医学市场报告的目标受众是该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
  • 相关人员可以透过各种用于分析奈米医学市场的策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场范围

  • 报告概述
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章：市场动态、监理及趋势分析

  • 市场动态
    • 司机
    • 抑制因素
    • 市场机会
  • 影响分析
  • 管道分析
  • 救赎方案
  • 流行病学
  • 竞争分析
  • 监管情景
  • 新产品发布
  • 合作关係与合约
  • 市场趋势

4. 2026-2033年全球奈米医学市场（依载体类型划分）

  • 脂质体
  • 聚合物
  • 奈米晶体
  • 无机物
  • 蛋白质
  • 其他的

5. 2026-2033年全球奈米药物市场（依应用领域划分）

  • 肿瘤学
  • 神经病学
  • 消炎（药）
  • 抗感染剂
  • 循环系统
  • 其他的

6. 2026-2033年全球奈米医药市场依通路划分

  • 医院药房
  • 零售药房
  • 网路药房

7. 2026-2033年全球奈米医学市场（按地区划分）

  • 北美洲
    • 我们
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太地区的其他国家
  • 中东
    • GCC
    • 以色列
    • 其他中东地区
  • 非洲
    • 南非
    • 中非
    • 北非

第八章 竞争情势

  • 热图分析
  • 公司简介
    • Abbott Laboratories
    • GlaxoSmithKline plc.
    • Eli Lilly and Company
    • Astrazeneca plc.
    • Novavax, Inc.
    • Stryker Corporation
    • OSI Pharmaceuticals
    • Kadmon Pharmaceuticals
    • Samyang Biopharm
    • Mitsubishi Tanabe Pharma Corporation
    • Kaken Pharmaceutical
    • Selecta Biosciences
    • Par Pharmaceutical
    • Cerulean Pharma Inc.
    • Navidea Biopharmaceuticals
    • AbbVie Inc.
    • AMAG Pharmaceuticals
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Celgene Corporation
    • Gilead Sciences, Inc.
    • JOHNSON &JOHNSON
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Hoffmann-La Roche AG
    • Sanofi SA
    • Shire Plc.
    • Teva Pharmaceuticals Industries Limited.

第九章各节

  • 参考
  • 调查方法
简介目录
Product Code: CMI2485

Nanopharmaceuticals Market is estimated to be valued at USD 1,89,000 Mn in 2026 and is expected to reach USD 7,62,000 Mn by 2033, growing at a compound annual growth rate (CAGR) of 22.1% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 1,89,000 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 22.10% 2033 Value Projection: USD 7,62,000 Mn

Nanopharmaceuticals are novel medicine with particle size less than 1 micron, which work on the principle of nanotechnology. Nanopharmaceuticals are widely used in drug delivery as a carrier for therapeutic compound or as a therapeutic compound. Nanopharmaceuticals are designed to target particular cells, tissue or a specific organ.

Market Dynamics

Increasing prevalence of cardiovascular diseases, cancer, and infectious diseases are major factors driving nanopharmaceuticals market growth. The World Health Organization, factsheet September 2018, estimated around 10 million cases of tuberculosis and around 1.6 million deaths from the disease in 2017. Moreover, advantages of nanopharmaceuticals over macroscopic level medicines is expected to boost the market growth. Nanopharmaceuticals can pass the blood brain barrier and can access the remote areas of brain as well as low solubility of the compound can be developed for enhancing its characteristics.

Key features of the study

  • This report provides in-depth analysis of the nanopharmaceuticals market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global nanopharmaceuticals market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Abbott, GlaxoSmithKline and plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
  • The global nanopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the nanopharmaceuticals market

Market Segmentation

  • By Carrier Type
    • Liposomes
    • Polymer
    • Nanocrystals
    • Inorganic
    • Protein
    • Others
  • By Application
    • Oncology
    • Neurology
    • Anti-inflammatory
    • Anti-infective
    • Cardiovascular
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
  • Key Players
    • Abbott
    • GlaxoSmithKline plc.
    • Eli Lilly and Company
    • Astrazeneca plc.
    • Novavax, Inc.
    • Stryker Corporation
    • OSI Pharmaceuticals
    • Kadmon Pharmaceuticals
    • Samyang Biopharm
    • Mitsubishi Tanabe Pharma Corporation
    • Kaken Pharmaceutical
    • Selecta Biosciences
    • Par Pharmaceutical
    • Cerulean Pharma Inc.
    • Navidea Biopharmaceuticals, Inc.
    • AbbVie Inc.
    • AMAG Pharmaceuticals
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Celgene Corporation
    • Gilead Sciences, Inc.
    • JOHNSON & JOHNSON
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Hoffmann-La Roche AG
    • Sanofi S.A
    • Shire Plc.
    • Teva Pharmaceuticals Industries Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Carrier Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Nanopharmaceuticals Market, By Carrier Type, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026 - 2033
    • Segment Trends
  • Liposomes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Polymer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Nanocrystals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Inorganic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Nanopharmaceuticals Market, By Application, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026 - 2033
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Anti-inflammatory
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Anti-infective
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Cardiovascular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Nanopharmaceuticals Market, By Distribution Channel, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026 - 2033
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Nanopharmaceuticals Market, By Region, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • North America
    • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of APAC
  • Middle East
    • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • South Africa
      • Central Africa
      • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Abbott Laboratories
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline plc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Eli Lilly and Company
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Astrazeneca plc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Novavax, Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Stryker Corporation
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • OSI Pharmaceuticals
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Kadmon Pharmaceuticals
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Samyang Biopharm
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Mitsubishi Tanabe Pharma Corporation
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Kaken Pharmaceutical
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Selecta Biosciences
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Par Pharmaceutical
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Cerulean Pharma Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Navidea Biopharmaceuticals
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • AbbVie Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • AMAG Pharmaceuticals
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Amgen Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Astellas Pharma Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Celgene Corporation
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Gilead Sciences, Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • JOHNSON & JOHNSON
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Merck & Co., Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Novartis AG
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Pfizer, Inc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Hoffmann-La Roche AG
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Sanofi S.A
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Shire Plc.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Teva Pharmaceuticals Industries Limited.
      • Company Overview
      • Product Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
      • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact